• AHA
  • ESC
  • ASCO
  • ACC
  • RSNA
  • ISC
  • SABCS
  • AACR
  • APA
  • Archives
株式会社ヘスコインターナショナルは、法令を遵守し本サイトをご利用いただく皆様の個人情報の取り扱いに細心の注意を払っております。


New postoperative therapies are needed for pancreatic cancer because too few patients benefit from chemoradiation

New postoperative therapies are needed for patients with pancreatic cancer because only a small percentage benefits from the current standard, chemoradiation, according to an article in the June issue of the Annals of Surgical Oncology.

John F. Gibbs, MD, and his American colleagues reviewed 7 select series to evaluate the effectiveness of adjuvant therapy for patients who had resections of pancreatic cancer. "Current evidence-based analysis demonstrates that an adjuvant therapy regimen as a standard of care is lacking," according to Dr. Gibbs. "We, therefore, believe that it should be used judiciously outside of clinical trials because its benefits are confined to only a fraction of patients treated by complete resection; patients with residual microscopic disease derived negligible benefits."

Approximately 30,000 new cases of pancreatic cancer will be diagnosed this year. However, only 15 percent of patients will be eligible for surgery, and only 20 percent of those patients will survive for 5 years. Therefore, the theoretical maximal benefit of adjuvant therapy is 10 to 20 percent.

Dr. Gibbs recommended, "Given the small impact that current adjuvant therapies have on this disease, clinicians should concentrate on developing new therapies to address pancreatic cancer." The authors suggested a multi-institutional approach to coordinate research efforts that would optimize the development of new therapies based on molecular and genetic data. The authors also noted that quality of life issues are important for patients and should be included in any future studies.




DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.